^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    BEND3 (BEN Domain Containing 3)

    i
    Other names: BEN Domain Containing 3, BEN Domain-Containing Protein 3, BEND3
    Associations

    News

    Trials
    2ms
    Integrated Pan-Cancer Profiling and Breast Cancer Validation Identify BEND3 as a Potential Prognostic and Immune Biomarker. (PubMed, Breast Cancer (Dove Med Press))
    Functional analysis indicates it may regulate key cancer pathways. Importantly, in vitro experiments confirm its tumor-promoting effects in breast cancer, providing a foundation for further study of BEND3's mechanisms and therapeutic implications.
    Journal • Tumor mutational burden • Pan tumor
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • BEND3 (BEN Domain Containing 3)
    11ms
    BEND3 promotes hepatocellular carcinoma progression and metastasis by activating the PI3K/AKT/mTOR pathway and inducing epithelial-mesenchymal transition. (PubMed, Clin Res Hepatol Gastroenterol)
    BEND3 is highly expressed in HCC and strongly correlates with poor clinical outcomes. Functional and mechanistic analyses indicate that BEND3 enhances HCC progression by promoting proliferation, migration and invasion via EMT induction and PI3K/AKT/mTOR pathway activation.
    Journal
    |
    BEND3 (BEN Domain Containing 3)
    over4years
    [VIRTUAL] The First-in-Class UBA1 Inhibitor, TAK-243, in Combination With Radiotherapy for YAP1 and BEND3 Biomarker-Defined Small Cell Lung Cancer (ASTRO 2021)
    Our results demonstrated that inhibiting the UPS using a selective UBA1 inhibitor, TAK-243, is an effective anti-cancer strategy for SCLC. We determined a distinct transcriptomic-stratified (YAP1low and BEND3high) population of SCLC that is sensitive to UBA1-inhibition therapy with TAK-243 as a single agent and a radiosensitizer.
    Combination therapy
    |
    YAP1 (Yes associated protein 1) • BEND3 (BEN Domain Containing 3)
    |
    YAP1 positive
    |
    TAK-243
    over4years
    The First-in-Class UBA1 Inhibitor, TAK-243, in Combination With Radiotherapy for YAP1 and BEND3 Biomarker-Defined Small Cell Lung Cancer. (PubMed, Int J Radiat Oncol Biol Phys)
    Our results demonstrated that inhibiting the UPS using a selective UBA1 inhibitor, TAK-243, is an effective anti-cancer strategy for SCLC. We determined a distinct transcriptomic-stratified (YAP1 and BEND3) population of SCLC that is sensitive to UBA1-inhibition therapy with TAK-243 as a single agent and a radiosensitizer.
    Journal • Combination therapy
    |
    YAP1 (Yes associated protein 1) • BEND3 (BEN Domain Containing 3)
    |
    YAP1 positive
    |
    TAK-243